Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour Amy Brown…
Read More
Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More